Anaemia correction in predialysis elderly patients: influence of the antihypertensive therapy on darbepoietin dose.
Anaemia and hypertension are common in patients with chronic renal insufficiency. The correction of anaemia with erythropoiesis stimulating agents (ESA) can improve survival and decrease the decline of renal function. Angiotensin converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (AIIRA) can also slow the progression of renal failure, but the blockade of the renin-angiotensin system can worsen anaemia. The aim of our study was to assess the impact of antihypertensive therapy (ACEI plus AIIRA) in the requirements of darbepoietin in a group of elderly predialysis patients. We included 71 patients (m = 39, f = 32), mean age of 76.3 years with a mean creatinine clearance of 17.5 ml/min. Patients were divided in two groups according to their antihypertensive therapy: G-I patients under ACEI or AIIRA therapy and G-II normotensive patients or hypertensive patients under antihypertensive drugs other than ACEI or AIIRA. The groups were compared regarding demographic, nutritional, biochemical and inflammatory parameters. We also compared the mean darbepoietin dose. In GI the mean dose of darbepoietin was higher than in GII (0.543 vs. 0.325 microg/kg/week, P = 0.032). We did not find any difference regarding other parameters analysed. We conclude that ACEI and AIIRA can increase the needs of darbepoietin in predialysis elderly patients. However, when formally indicated to treat hypertension in a specific patient, they should not be switched to another antihypertensive agent. Instead, in such cases, higher doses of ESA should be used, if necessary.
Neves
Pedro Leão
PL
Serviço de Nefrologia, Hospital Distrital de Faro, Rua Leão Penedo, Faro, Portugal. plneves@hdfaro.min-saude.pt
Baptista
Alexandre
A
Morgado
Elsa
E
Iglesias
Alfonso
A
Carrasqueira
Hermínio
H
Faísca
Marília
M
Soares
Carla
C
Silva
Ana P
AP
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007674:Kidney Diseases / Q000150:complications*; D008297:Male
D000959:Antihypertensive Agents; D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa